Hospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2021

  1. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97

2019

  1. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  2. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

  3. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

  3. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

    Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948

  4. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

  2. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

    World Journal of Gastroenterology, Vol. 23, Núm. 41, pp. 7459-7469

  3. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2011

  1. La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados

    Gastroenterologia y Hepatologia, Vol. 34, Núm. 2, pp. 69-74

2010

  1. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression

    Hepatology, Vol. 51, Núm. 1, pp. 255-266

2009

  1. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

    Hepatology, Vol. 50, Núm. 6, pp. 1702-1708

2007

  1. Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial

    Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95

2006

  1. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis

    AIDS Research and Human Retroviruses, Vol. 22, Núm. 12, pp. 1236-1241

2005

  1. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis

    Hepatology, Vol. 41, Núm. 4, pp. 779-789

1999

  1. Acute liver injury associated with the use of ebrotidine, a new H2- receptor antagonist

    Journal of Hepatology, Vol. 31, Núm. 4, pp. 641-646